Harvard's Gregory Verdine has big ambitions for his miniprotein 'braces' — and now $107M to guide them to the clinic
Harvard scientist Gregory Verdine’s mission has always been clear: drug the undruggable. He’s now one step closer, with $107 million in the bank to bring a new class of drugs to the clinic — and he isn’t ruling out an IPO.
Since launching FogPharma in 2016, Verdine and his crew have been hard at work on a new kind of therapeutic class that combines the cell-penetrating capacity of small molecules with the target-engaging tenacity of biologics. The result is what he calls CPMPs, or cell-penetrating miniproteins.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 106,500+ biopharma pros reading Endpoints daily — and it's free.